How to Use Red Light Therapy for Lungs: Methods and Insights

Red light therapy for lungs is an experimental approach that uses specific wavelengths of red and near-infrared light, typically between 630 and 980 nanometers, to reduce pulmonary inflammation and support tissue repair. The technique goes by the clinical name photobiomodulation (PBM), and the research so far is promising but heavily weighted toward animal studies and small clinical case series. No major health agency currently recommends it as a standalone lung treatment, yet the underlying biology is plausible enough that researchers are actively testing it for conditions ranging from chronic obstructive pulmonary disease (COPD) to post-viral lung damage.

What Red and Near-Infrared Light Actually Do Inside Tissue

The core idea behind photobiomodulation is that certain components of your cells respond to specific wavelengths of light. The most widely studied target is the mitochondrial electron transport chain, which is photosensitive to red and near-infrared light. When these wavelengths hit mitochondria, the result is a boost in ATP production and a brief spike in reactive oxygen species, which at low levels acts as a signaling molecule that kicks off protective cellular responses.¹ Think of it as a mild cellular stress that triggers a repair cascade, somewhat analogous to how controlled exercise stresses muscles and makes them stronger.

In lung tissue specifically, the downstream effects researchers care about are anti-inflammatory. Preclinical work consistently shows that photobiomodulation dials down key inflammatory signals. A meta-analysis of preclinical and clinical data found that PBM significantly reduced the expression of two major pro-inflammatory markers, TNF-alpha and IL-1 beta, in lung tissue while simultaneously boosting IL-10, an anti-inflammatory cytokine.² That shift from a pro-inflammatory to an anti-inflammatory profile is exactly what you’d want in conditions where the lungs are being damaged by the body’s own immune overreaction.

Animal research has also explored how red light affects immune cell behavior in the lungs. In a mouse model of sepsis-induced acute lung injury, 630-nanometer LED light inhibited a particular type of immune cell activation (M1 macrophage polarization) that drives tissue destruction during severe lung inflammation.³ In plain terms, the light seemed to calm the immune cells that were causing the most damage.

The Penetration Challenge

The lungs sit behind the ribcage, layers of muscle, and connective tissue. Getting therapeutic light through all of that is the single biggest practical hurdle. Unlike skin conditions where you can shine a device directly on the target, lung therapy requires light to travel several centimeters through dense tissue before it reaches the airways and alveoli.

Red light in the 630-660 nanometer range penetrates tissue less deeply than near-infrared light around 810-980 nanometers. Studies measuring how much light makes it through several centimeters of tissue have found that at higher power settings, only a small fraction of near-infrared energy reaches that depth. One study using 810-nanometer light at 10-15 watts found that roughly 0.5% to 3% of the surface energy penetrated 3 centimeters of tissue.⁴ That study was conducted with skull and brain tissue rather than the chest wall, so the numbers are not perfectly transferable, but they illustrate the general challenge: you lose the overwhelming majority of photons before they reach any organ sitting deep inside the body.

The chest wall varies in thickness depending on the person, and the intercostal spaces between ribs offer slightly less resistance than bone. Some researchers position light sources over these intercostal areas to maximize what reaches the lungs. Still, anyone considering this therapy should understand that a low-power consumer LED panel held against the chest is delivering a tiny fraction of its rated output to actual lung tissue, if any measurable amount at all. Higher-power clinical devices produce more penetration, but they also require careful dosing to avoid heating tissue.

Delivery Methods That Have Been Studied

Researchers have tried several ways to get therapeutic light to the lungs, and each has different tradeoffs.

Transcutaneous Application

This is the most straightforward approach: placing LED clusters or laser diodes against the chest wall and shining light through the skin and ribcage toward the lungs. In two published case reports, patients with acute infectious respiratory syndrome were treated with 630 and 660-nanometer light applied transcutaneously about 7 centimeters above the chest area, irradiating the lung and heart regions. The patients showed improvement in respiratory symptoms and oxygen levels.⁵ This is encouraging but represents only two patients without a control group, so the results need to be interpreted cautiously.

In animal studies, transcutaneous delivery has been more rigorously tested. A study on infrared LED photobiomodulation in COVID-19 patients noted that researchers had previously observed significant decreases in pulmonary edema, neutrophil influx, and multiple pro-inflammatory signals when light was delivered to lung tissue.⁶ The idea is that even the small percentage of photons that penetrate to the lung surface may be enough to trigger a meaningful anti-inflammatory response in the outermost tissue layers, especially when applied repeatedly over multiple sessions.

Intravascular Laser Irradiation of Blood

A fundamentally different approach, intravascular laser irradiation of blood (ILIB) involves threading a thin fiber-optic probe into a vein and irradiating the blood directly as it circulates. This bypasses the penetration problem entirely, since the light hits blood cells as they flow past the fiber tip. Research has observed that ILIB improved lung compliance and gas exchange efficiency in asthmatic patients, and the technique has shown usefulness in conditions involving low oxygen levels and impaired gas exchange.⁷ The logic here is that photobiomodulation of circulating blood cells, particularly white blood cells, may modulate the systemic inflammatory response that drives lung damage.

ILIB is obviously not a home therapy. It requires clinical supervision, intravenous access, and specialized equipment. But for severe lung conditions where transcutaneous delivery may not penetrate deeply enough, it represents an alternative route that some clinicians in certain countries have explored.

Lung Conditions Where PBM Has Been Investigated

The evidence base is not equally deep across all lung diseases. Here is where things stand for the conditions that have attracted the most research attention.

Chronic Obstructive Pulmonary Disease

COPD has been one of the more studied targets. A narrative review of the available evidence found that PBM can reduce lung inflammation by lowering inflammatory cytokines and chemokines at multiple levels while increasing anti-inflammatory cytokines. The review also noted that PBM improved both peripheral and respiratory muscle metabolism and promoted the growth of new blood vessels in the treated area.⁸ This muscle metabolism benefit is particularly relevant for COPD patients, who often suffer from skeletal muscle wasting and respiratory muscle fatigue alongside their airway inflammation. Some of the COPD studies have applied PBM to the chest wall, while others have targeted peripheral muscles during exercise, with the goal of improving exercise tolerance indirectly.

Asthma

A recent dosimetric study in a mouse model of chronic asthma found that photobiomodulation reduced mucus production and collagen deposition in the airways, with the most pronounced effects at intermediate energy doses of 3 and 5 joules. The therapy effectively modulated immune responses, reduced airway remodeling, and attenuated chronic pulmonary inflammation.⁹ Airway remodeling is a major problem in chronic asthma because repeated inflammation gradually thickens airway walls and makes them less responsive to bronchodilators. If PBM could slow that process, it would address something that current asthma medications do not handle well. But these are mouse results, and human airways differ in important ways.

Pulmonary Fibrosis

Idiopathic pulmonary fibrosis is a condition where scar tissue progressively replaces normal lung tissue, and current treatments only slow the decline rather than reversing it. In a mouse model, low-level laser therapy reduced both the migration of inflammatory cells and the deposition of collagen fibers in the lungs. It also downregulated pro-inflammatory signals while boosting anti-inflammatory ones, and it greatly reduced TGF-beta, a key driver of fibrotic scarring. Remarkably, the inflammatory parameters in laser-treated mice showed no statistical difference from those in healthy control mice, suggesting the therapy essentially normalized the inflammatory environment.¹⁰ This is a striking result in an animal model, but translating it to human lungs with established fibrosis would be a different matter.

Post-Viral Lung Inflammation

The COVID-19 pandemic generated a burst of interest in PBM for virus-damaged lungs, since severe COVID often involved an inflammatory cascade that destroyed lung tissue even after the virus had been cleared. Several small studies explored whether photobiomodulation could calm this overactive immune response. The meta-analysis referenced earlier specifically examined COVID-related evidence and found the anti-inflammatory shifts described above.² The rationale extends beyond COVID to any viral pneumonia where immune-mediated damage overshadows direct viral injury.

Why Dose Matters More Than You Might Expect

One of the most consistent findings in photobiomodulation research is that more light is not better. A well-established biphasic dose response, sometimes called the Arndt-Schulz curve, means that low levels of light stimulate and repair tissue while higher doses can actually inhibit healing or cause harm.¹¹ This creates a narrow therapeutic window, and it is one reason why the parameters used in studies, including wavelength, power density, total energy delivered, and session duration, vary widely and sometimes produce contradictory results.

The asthma dosimetry study illustrates this directly: intermediate energy doses of 3 and 5 joules outperformed both lower and higher doses.⁹ For anyone considering this therapy, the implication is that simply buying a more powerful device and using it longer is not a sound strategy. The optimal dose for lung tissue is not yet established in humans, and getting it wrong could mean the difference between a beneficial anti-inflammatory effect and no effect at all.

Professional devices used in clinical research typically specify power density (milliwatts per square centimeter at the tissue surface), total energy delivered per point (joules), and wavelength. Consumer devices marketed for general wellness rarely provide these specifications at a level of precision that would let you replicate the parameters used in published studies. If you are interested in pursuing this, working with a practitioner who understands dosimetry and can adjust parameters based on your body composition and the specific condition being treated is a much sounder approach than self-treating at home.

Safety and What to Watch For

Red light therapy is generally considered low risk, which is part of its appeal. There is no ionizing radiation involved, and the wavelengths used do not carry enough energy to damage DNA the way ultraviolet light can. The main acute risk is thermal injury if a high-power device is held against the skin for too long, which is manageable with proper protocols.

A more nuanced concern involves applying light therapy to areas where cancer may be present. A preliminary study examining whether red light phototherapy affected tumor growth in tissues harboring cancer found no measurable effect of low-level laser therapy on tumor progression at the parameters tested, suggesting that PBM at those settings may be safe even when malignant lesions are present.¹² However, the researchers themselves called for further study. The concern is theoretical but not irrational: since PBM promotes cellular metabolism and proliferation, there has been worry that it could accelerate the growth of existing tumors. The available data so far does not support that fear at standard therapeutic doses, but if you have a known or suspected lung malignancy, this is a conversation to have with an oncologist before proceeding.

Other practical safety points include eye protection when using high-power near-infrared devices, since these wavelengths are invisible but can damage the retina, and caution around photosensitizing medications that could amplify the tissue response. Pregnant individuals and people with active infections in the treatment area should also consult a clinician before using PBM.

How PBM Compares to Conventional Lung Treatments

One of the more interesting claims in the literature is that the anti-inflammatory effect of low-level light therapy may be comparable in magnitude to that of non-steroidal anti-inflammatory drugs. A review of the COPD evidence noted this comparison and added that, unlike corticosteroids and other immunosuppressive medications that produce systemic side effects, PBM primarily exerts local effects with little to no systemic impact.⁸ That profile is attractive for people who experience side effects from long-term steroid use, which is common in COPD and asthma management.

That said, the same review was clear that PBM is not a replacement for existing pharmacotherapy or pulmonary rehabilitation. The evidence supports it as an adjunctive tool, something that might be layered on top of standard care to improve outcomes. For conditions like COPD, where the combination of bronchodilators, inhaled steroids, pulmonary rehabilitation, and sometimes supplemental oxygen represents the standard of care, PBM would slot in as an additional modality rather than a substitute for any of those. Anyone who stops taking prescribed lung medications to replace them with a light therapy panel is making a dangerous trade.

What the Gaps in the Evidence Actually Look Like

The honest picture of this field is one of strong mechanistic plausibility, good preclinical results, and very limited human data. Most of the controlled studies showing clear anti-inflammatory effects in lung tissue were conducted in mice or rats, where researchers can use precise doses and directly examine lung tissue afterward. Translating those results to humans introduces uncertainties that have not yet been resolved: how much light actually reaches human lung tissue through the chest wall at tolerable power levels, what the optimal dose and treatment schedule are, and whether the effects seen in animal models hold up in the much more complex human immune environment.

The human evidence that does exist consists mostly of case reports and small uncontrolled studies. The two case reports of respiratory syndrome treatment, while promising, represent the lowest rung of clinical evidence. The COVID-era studies often lacked proper control groups because they were conducted under emergency conditions. Registered clinical trials are exploring PBM for COPD, but published results from large randomized controlled trials are still scarce.

This does not mean the therapy is ineffective. It means the evidence is immature. Researchers in the field are generally optimistic based on the mechanistic data, but the gap between “this works in a mouse lung” and “this reliably helps a person with COPD breathe better” is substantial and has swallowed many initially promising therapies in other fields.

Practical Considerations for the Curious

If the research has caught your attention and you want to explore red light therapy for a lung condition, a few practical realities are worth keeping in mind. First, wavelength matters. The studies showing lung-specific effects have primarily used wavelengths in the 630-660 nanometer (visible red) and 810-980 nanometer (near-infrared) ranges. A general “red light” device that emits at a different wavelength may not produce the same biological response. Check the specifications before assuming any red light panel is relevant.

Second, positioning matters. Given the penetration challenge, applying light over the intercostal spaces on both the anterior and posterior chest wall, rather than over bone, gives photons the best chance of reaching lung tissue. Some practitioners use multiple application points per session to cover more lung area. The duration per point in published protocols varies from about 30 seconds to several minutes, depending on the power output of the device.

Third, consistency matters. The animal studies showing the most robust effects typically used repeated daily treatments over a period of days to weeks. A single session is unlikely to produce a lasting anti-inflammatory shift. If you try this, plan for a course of treatments rather than a one-off experiment.

Finally, track something measurable. Peak flow readings, oxygen saturation with a simple pulse oximeter, exercise tolerance, or symptom diaries can give you a rough sense of whether anything is changing. Without some form of objective tracking, the placebo response and normal day-to-day variation in lung symptoms will make it impossible to tell whether the therapy is doing anything.